Free Trial

Boston Partners Has $2.93 Million Stock Holdings in Clarivate Plc (NYSE:CLVT)

→ Protect Your Bank Account from China (From Behind the Markets) (Ad)
Clarivate logo with Computer and Technology background

Boston Partners reduced its holdings in Clarivate Plc (NYSE:CLVT - Free Report) by 42.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 316,204 shares of the company's stock after selling 230,467 shares during the quarter. Boston Partners' holdings in Clarivate were worth $2,928,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Canada Pension Plan Investment Board boosted its stake in shares of Clarivate by 1,614.5% during the 3rd quarter. Canada Pension Plan Investment Board now owns 1,119,600 shares of the company's stock worth $7,513,000 after buying an additional 1,054,300 shares during the last quarter. Public Sector Pension Investment Board bought a new position in Clarivate in the third quarter valued at approximately $6,710,000. Clarkston Capital Partners LLC increased its position in shares of Clarivate by 12.0% during the 3rd quarter. Clarkston Capital Partners LLC now owns 57,567,115 shares of the company's stock worth $386,275,000 after purchasing an additional 6,172,694 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Clarivate by 2.9% during the 3rd quarter. HighTower Advisors LLC now owns 144,539 shares of the company's stock worth $969,000 after purchasing an additional 4,099 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Clarivate by 868.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 45,325 shares of the company's stock valued at $304,000 after buying an additional 40,643 shares during the last quarter. 85.72% of the stock is owned by institutional investors.


Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Oppenheimer dropped their price target on shares of Clarivate from $11.00 to $10.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 28th. Royal Bank of Canada lowered their price target on Clarivate from $10.00 to $8.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 28th. The Goldman Sachs Group cut their price objective on Clarivate from $8.50 to $7.50 and set a "buy" rating for the company in a research report on Thursday, May 9th. Morgan Stanley decreased their target price on Clarivate from $9.00 to $8.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 28th. Finally, Barclays cut their price target on Clarivate from $7.00 to $6.00 and set an "underweight" rating for the company in a report on Wednesday, February 28th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, Clarivate currently has an average rating of "Hold" and a consensus target price of $7.78.

Check Out Our Latest Stock Analysis on Clarivate

Clarivate Stock Performance

Clarivate stock traded down $0.17 during midday trading on Friday, hitting $6.01. The company's stock had a trading volume of 5,918,450 shares, compared to its average volume of 4,437,370. The company has a debt-to-equity ratio of 1.03, a current ratio of 0.86 and a quick ratio of 0.86. The company has a market cap of $4.02 billion, a price-to-earnings ratio of -3.62, a PEG ratio of 1.55 and a beta of 1.24. Clarivate Plc has a 1-year low of $5.99 and a 1-year high of $10.03. The company has a 50-day moving average price of $7.03 and a two-hundred day moving average price of $7.86.

Clarivate (NYSE:CLVT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.21 EPS for the quarter, meeting analysts' consensus estimates of $0.21. Clarivate had a positive return on equity of 10.11% and a negative net margin of 39.29%. The business had revenue of $683.70 million during the quarter, compared to the consensus estimate of $687.80 million. During the same quarter in the previous year, the firm earned $0.20 earnings per share. Clarivate's revenue for the quarter was up 1.2% compared to the same quarter last year. As a group, sell-side analysts predict that Clarivate Plc will post 0.62 earnings per share for the current year.

Clarivate Profile

(Free Report)

Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications.

Featured Articles

Institutional Ownership by Quarter for Clarivate (NYSE:CLVT)

→ Write this ticker symbol down… (From StocksToTrade) (Ad)

Should you invest $1,000 in Clarivate right now?

Before you consider Clarivate, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clarivate wasn't on the list.

While Clarivate currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

JNJ shares hit a low, trading near $145 at under 14X earnings. With a high dividend yield, it's poised for a rebound.

Recent Videos

Roaring Kitty’s GameStop Gamble: What Went Wrong?
Will FOMC Push Stocks Higher? Here’s What to Expect
Unlock Growth: Understanding Dividend Yield

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines